Home › Liver Diseases › Texas › Dallas
Liver Diseases clinical trials in Dallas, TX
5 studies for Liver Diseases are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
Recruiting
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RecruitingPhase 1
- Clinical Trial Site, Dallas
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
RecruitingPhase 2
- University of Texas Southwestern Medical Center, Dallas
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- UT Southwestern Medical Center, Dallas
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
RecruitingObservational study
- Baylor College of Medicine (Scott & White), Dallas
About Liver Diseases
Get the facts about liver diseases, such as hepatitis, cancer, and cirrhosis. Know your risk and what you can do to prevent liver problems.
More about Liver Diseases on MedlinePlus
Liver Diseases trials in other cities
- Houston, TX10 studies
- Chicago, IL9 studies
- Washington, DC8 studies
- Los Angeles, CA7 studies
- Atlanta, GA7 studies
- Philadelphia, PA6 studies
- Richmond, VA6 studies
- New York City, NY6 studies
- San Antonio, TX6 studies
- Durham, NC5 studies
- Ann Arbor, MI5 studies
- Cincinnati, OH4 studies
Other studies in Dallas
- Breast Cancer54 studies
- Non-Small Cell Lung Cancer53 studies
- Metastatic Cancer44 studies
- Heart Failure42 studies
- Cancer (all types)40 studies
- Prostate Cancer39 studies
- Colorectal Cancer34 studies
- Obesity33 studies
- Ovarian Cancer31 studies
- Bladder Cancer27 studies
- Lung Cancer26 studies
- Endometrial Cancer25 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.